Introduction {#Sec1}
============

Cellular angiofibroma (CA) belongs to soft tissue tumours that predominantly occur in the distal genital tract of both genders: vulvo-vaginal region in women and inguino-scrotal area in men \[[@CR1], [@CR2]\], although extragenital localizations have also been described \[[@CR3]--[@CR5]\].

The first soft tissue tumour with a relatively pelvic site-specificity was a benign stromal polyp described in the early 1960 \[[@CR6]\].

Among the mesenchymal tumours involving the vulva, we can distinguish the lesions that can arise at any site, including the vulva, and those more characteristics of this area. The former group includes leiomyoma (Fig. [1](#Fig1){ref-type="fig"}), lipoma (Fig. [2](#Fig2){ref-type="fig"}) and solitary fibrous tumour (Fig. [3](#Fig3){ref-type="fig"}) while the second group includes CA (Fig. [4](#Fig4){ref-type="fig"}) along with aggressive angiomyxoma (Fig. [5](#Fig5){ref-type="fig"}), angiomyofibroblastoma (Fig. [6](#Fig6){ref-type="fig"}) and fibroepithelial stromal polyp \[[@CR7]\].Fig. 1Leiomyoma at hematoxylin-eosin, 200XFig. 2Lipoma at hematoxylin-eosin, 200XFig. 3Solitary fibrous at hematoxylin-eosin, 200XFig. 4Cellular angiofibroma at hematoxylin-eosin, 200XFig. 5Aggressive angiomyxoma at hematoxylin-eosin, 200XFig. 6Angiomyofibroblastoma at hematoxylin-eosin, 200X

Cellular angiofibroma is a rare benign mesenchymal lesion, first described by Nucci et al. in 1997 \[[@CR1]\] in a series of 6 cases that occurred almost exclusively in the vulva of middle-aged women. A short time later, Laskin et al. \[[@CR2]\] described 11 cases of a histologically similar lesion named "angiomyofibroblastoma-like" tumour, which affects the adult men in the inguino-scrotal area. The World Health Organization classification \[[@CR8]\] established that the term "Cellular angiofibroma" includes this kind of lesion in both females and males, because there are no reproducible morphologic differences between the two genders. Macroscopically these lesions are commonly well circumscribed, localized in the superficial soft tissue and are characterized by 2 main components: bland spindle cells and small to medium-sized vessels with mural hyalinization \[[@CR9]\].

Since the first description by Nucci, only few studies have been published in the literature, most of which consisted of single case-reports or reviews which include cases from both genders.

Here, we reviewed all the cases of CA arising in women since 1997, to clarify the outcome and to identify the best treatment.

Review {#Sec2}
======

Materials and methods {#Sec3}
---------------------

We collected and analyzed the published articles in the literature regarding CA from January 1997 to December 2014, using Pubmed research and the terminologies "cellular angiofibroma", "vulvovaginal mesenchymal tumour", "vulvovaginal benign tumour", "vulvovaginal stromal tumour" and "vulvovaginal soft tissue tumour". We selected only the cases involving the female gender: a total of 79 published cases of CA were found. Where possible, we contacted the authors to update the follow-up data, in particular regarding local recurrences and/or metastases.

In the Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} are reported the main clinical features of the 74 vulvo-vaginal and pelvic CA and the clinical finding of the 6 extra-pelvic CA, respectively.Table 1Clinical features of 74 cases of Cellular Angiofibroma in vulvo-vaginal and pelvic regionsCaseAgeAuthorSiteSize (media, cm)TreatmentFollow-up (Months)Recurrence150NucciVulva1,2Simple excisionUKUK246NucciLab maj2Local excision + 2 reexcisions19NER339NucciLab2,15Simple excision12NER449NucciLab1,2Simple excisionUKUK543NucciVulva2,3UKUKUK641Nucciperineum3UKUKUK737ColombatLab2,5UKUKUK837CurryClitoral Hood3,5UK15UK953DufauLab maj3,3UKUKUK1046DargentLab maj2,33Simple excision149NER1149DargentClitoris2,66Simple excision161NER1249IwasaLab maj2Simple excision5UK1339IwasaVulva/UKUKUK1446IwasaLab maj2Simple excision168NER1550IwasaVulva1,5Simple excisionUKUK1642IwasaVulva3Simple excision75NER1742IwasaPerineum/UKUKUK1875IwasaVulva2,8Simple excision59Died for Breast cancer1927IwasaLab maj1,1Local excision + reexcision50NER2041IwasaVulva2,7Simple excision54NER2168IwasaVulva/Simple excision17NER2259IwasaLab maj2Simple excision41NER2349IwasaVulva/UKUKUK2437IwasaHymen4,8Local excision with positive margins24NER2538Iwasavagina/UKUKUK2646IwasaVulva2,9Simple excision35NER2747IwasaLab maj1,4Simple excision44NER2822IwasaInguinal region12Local excision + reexcision18NER2952IwasaUrethra/UKUKUK3047IwasaVulva/UKUKUK3148IwasaLab maj3Simple excision8NER3224IwasaVagina11UK6NER3331IwasaPerineum4Simple excisionUKUK3458IwasaVagina0,6Simple excisionUKUK3550IwasaVulva1,8Simple excision6NER3658IwasaVulva3Simple excision9NER3750IwasaVulva/UKUKUK3849McCluccageLab maj4Simple excision6Local recurrence3920McCluccageNot specified2,4Simple excision240NER4065McCluccageLab maj5Simple excision12NER4159McCluccageVulva2Simple excision18NER4258ChenVulva2,7Piecemeal excision75NER4352ChenVulva3Simple excision27NER, died for cancer of UK origin4434ChenVulva1,2Simple excisionUKUK4532ChenVulva4,85Simple excisionUKUK4625ChenVulva1,3Simple excision42NER4743ChenVulva2,5Simple excision2NER4859ChenVulva1,3Simple excision14NER4946ChenVulva6,5Simple excision4NER5071ChenVulva7,5Simple excisionUKUK5139ChenVulva/Simple excision7NER5246ChenVulva2Simple excisionUKUK5341FluckePerineum3Simple excisionUKUK5439FluckeVagina1Local excision with positive margins75NER5550FluckeVulva3Local excision + reexcision55NER5651FluckeLab maj2,7Marginal excision66NER5744FluckeLab maj2,3Simple excisionUKUK5850FluckeVulva4Local excision with positive marginsUKUK5948FluckeVulva8,5Simple excisionUKUK6042FluckeVulva2,2Simple excisionUKUK6163FluckeClitoris2,5Local excision with positive margins38NER6227FluckeLab maj8Marginal excisionUKUK6342FluckeVulva1,7Simple excision30UK6446FluckeLab maj3Marginal excisionUKUK6555FluckeVulva2,3Simple excision12NER6657FluckeVulva4,5Simple excision6NER6747FluckeVulva1,5Local excision with positive marginsUKUK6839FluckeVagina9Marginal excisionUKUK6951Rua MichelettiLab maj4,6Simple excision112NER7031KerkutaLab maj4Simple excision10NER7177LaneLab4Simple excision12NER7226ArsenovicVulva8,5Simple excision90NER7355MaggianiVagina12,3UKUKUK7420AhmadniaBoth lab maj/Simple excision12NER*NER* not evidence of recurrence, *UK* unknownTable 2Clinical features of 6 cases of extra-pelvic Cellular AngiofibromaCaseAgeAuthorSiteSize (media, cm)TreatmentFollow-up (Months)Recurrence7552ChenLeft hip3,5Local excision + reexcisionUKUK7663FluckeKnee lateral4Simple excision45NER7743Val-BernalChest wall7Simple excision203NER7838Val-BernalLeft hypocondrium3,5Simple excision104NER7960MandatoRetroperitoneim pelvicc3,9Simple excision6NER8020AhmadniaLeft axilla + both breast/Simple excision12NER*NER* not evidence of recurrence, *UK* unknown

Results {#Sec4}
-------

### Clinical features {#Sec5}

The 79 affected women have an age at presentation ranging from 20 to 77 years (mean 46.1 years). The most common anatomic site is the vulvo-vaginal region, in particular labium majus area and vulva overall (18 and 35 cases, respectively). Outside the vulvo-vaginal region, 5 pelvic localizations are reported, including 4 perineum and an urethral site. Six extra-pelvic CA are reported, such as a left hip, lateral knee, chest wall, left axilla and breasts \[[@CR10]\], left hypocondrium \[[@CR3], [@CR5]\] and more recently, we have reported the first case of retroperitoneal CA arising in right paravesical space of a post-menopausal woman \[[@CR11]\].

The tumour size ranges from 0.6 to 12.3 cm, with a mean size of 3.6 cm. A clinical diagnosis before surgery is reported only in 25 cases. Among these, the most common clinical presentation resembles a Bartholin's cyst (12/25, 48 % of cases), a not-specific solid mass (7/25, 28 % of cases), vulval cyst (3/25, 12 % of cases), leyomioma (2/12, 8 % of cases) and lipoma (1/25, 4 % of cases). In 8 cases of CA the time occurred between the tumour's occurrence and the surgical treatment is reported: the mean is 16.6 month, ranging from 2 to 36 months.

CA is usually treated by simple excision; the involvement or not of the surgical margins is reported in 47/78 (60.2 %) CA with 18 positive surgical margins (18/47, 38.2 %) and 29 negative surgical margins (29/47, 61.7 %); only 5 cases (5/18, 27.8 %) of re-excision because involved the surgical margin are reported.

Follow-up data are reported in 48/79 (60.7 %) cases with a range of 3--240 months (mean 46.6 months): the available follow-up data show that CA tends to not develop local recurrences or metastasis also in case of atypia or sarcomatous transformation. In 7 of the 12 patients with atypia or sarcomatous transformation follow up data were available, no recurrence or metastases were reported after a median follow-up of 14 months \[[@CR9]\].

One patients died of metastatic carcinoma of unknown primary origin, after 27 months from the diagnosis of CA with sarcomatous component. In an another one, the women died of breast cancer, 59 months after the CA diagnosis, without CA recurrence or metastases found meanwhile.

Only a local recurrence of vulvar CA is described after 6 months follow-up \[[@CR12]\]. CA has been initially excised with a rim of free-tumour tissue \[[@CR12]\].

### Pathological features {#Sec6}

A macroscopic/microscopic description was reported in 63/79 (79.7 %) CA. Grossly, the neoplasm is described as white or yellowish nodules, mostly firm and partly gelatinous of cystic in appearance, with a cut surface white tan to grayish in color. Macroscopically, three cases is recorded as polypoid lesions \[[@CR13]\] and in other few cases is appreciated a multilobulated appearance. CA is usually well-circumscribed, although focal extension into surrounding soft tissue can be seen. Most lesions were found in superficial soft tissue while 5 cases, all in the vulvovaginal region, involve dermis \[[@CR3]\]. There is reported only one case with foci of haemorrhage \[[@CR3]\] and none showing foci of necrosis.

Microscopically, the CA is a cellular neoplasm, composed of bland spindle shaped cells, proliferating in an edematous to fibrous stroma, containing wispy collagen bundles, numerous small to medium-sized thick-walled, often hyalinized, vessels and a minor component of adipose tissue \[[@CR7]\]. The spindle cell component in most cases is quite cellular and randomly distributed throughout the lesion, focally forming short fascicles but generally without any particular pattern \[[@CR3]\]. The spindle cells usually have short, fusiform, ovoid, sometimes tapering or polygonal nuclei with incospicuous nucleoli, while their cytoplasm is palely eosinophilic with indistinct, ill-defined borders or bipolar dendritic processes. Nuclear grooves and intranuclear inclusions are commonly observed \[[@CR13]\]. A moderate number of inflammatory cells, comprising lymphocytes and rarely neutrophils, are scattered throughout the stroma \[[@CR3]\]; the mast cells are often abundant while multinucleated giant cells or epithelioid cells are absent in this neoplasm.

Mitotic activity is very variable: indeed, a prominent mitotic activity may be occasionally observed, and abnormal mitoses and cellular atypia are rarely present.

CA with atypia or sarcomatous trasformation was reported in 12 women \[[@CR9]\], no necrosis or hemorrhage was observed in any case and the atypical or sarcomatous component wasn't morphologically recognizable on macroscopically examination. Microscopically, the atypical changes ranged from severely atypical cells disseminated within a background of usual CA to the formation of a discrete atypical foci. Similarly, the sarcomatous component showed variable features, including an atypical lipomatous tumour-like component, pleomorphic liposarcoma and pleomorphic sarcoma \[[@CR9]\].

### Immunohistochemical features {#Sec7}

In the Table [3](#Tab3){ref-type="table"} are summarized the available data about the immunohistochemical findings of the selected articles. Immunohistochemical findings were reported only in 44/79 (55.7 %) published CA because many articles don't distinguish the immunohistochemical features between the male and female tumours.Table 3Immunohistochemical features of cellular angiofibroma in women reported in literatureCaseAuthorVimentinCD34S-100α-SMADesminKeratinEMAERPRh-CaldesmonCD10CD99CD31CD1171Nucci+\-\-\-\-\--2Nucci+\-\-\-\-\--3Nucci+\-\-\-\-\--4Nucci+\-\-\-\-\--5Nucci+6Nucci+10Dargent++-+\--++-+\--11Dargent+\--++-+\--12Iwasa+-++++13Iwasa+-++++14Iwasa+-+-++15Iwasa+-+-++16Iwasa+\-\--++17Iwasa+\-\-\--+18Iwasa+\-\-\--+19Iwasa+\-\-\--+20Iwasa+\-\-\--+21Iwasa+\-\-\-\--22Iwasa+\-\--23Iwasa\-\-\--24Iwasa\-\-\--25Iwasa\-\-\--26Iwasa\-\-\--27Iwasa\-\-\--28Iwasa\-\-\--29Iwasa\-\-\--30Iwasa\-\-\--31Iwasa\-\-\--32Iwasa\-\-\--33Iwasa\-\-\--34Iwasa\-\-\--35Iwasa\-\-\--38McCluccage+\-\-\--+++\--39McCluccage++\-\-\-\--40McCluccage++\-\-\--++-+41McCluccage+\-\-\-\--++\--69Rua Micheletti+\-\-\--70Kerkuta+\-\-\--++71Lane++\-\--++74Arsenovic++\-\--++73Maggiani\--+-++76Val-Bernal++\-\-\-\--++77Val-Bernal+\-\-\--78Mandato++*SMA* smooth muscle actin, *EMA* epithelial membrane antigen, *ER*/*PR* estrogen/progesterone receptor

Tumour cells are consistently negative for S-100protein (40/40 cases, 100 %), while they show positivity for CD34 in 45.4 % (20/44) of the cases. The CD34 positivity, together with typical muscle-markers positivity, as α-SMA and desmin, in an extremely minority of tumours (α-SMA positivity in 6 cases on 40 tested, 15 % and desmine positivity in 2/39 examined cases, 5.1 %), suggest a probable fibroblastic rather than myofibroblastic differentiation. When examined, the tumour cells also show an immunoreactivity for Vimentin. Another interesting finding is the expression of Estrogen receptor and/or Progesterone receptors by neoplastic cells \[[@CR5], [@CR14]--[@CR16]\], which can suggests the role of an hormonal disturbance in the pathogenetic mechanisms of this tumour. When evaluated, all cases of CA show h-Caldesmon negativity (5/5 cases, 100 %) and Keratin negativity (6/6 cases, 100 %).

Multifocal or diffuse p16 expression is present in the atypical or sarcomatous areas of the CA, whilst is scattered or absent in usual CA \[[@CR9]\]. In Table [4](#Tab4){ref-type="table"} are summarized the immunohistochemical findings in the other soft tissue tumors compared with CA \[[@CR17], [@CR18]\].Table 4Immunohistochemical features of CA and vulvar tumours for differential diagnosisVimentinCD34S-100α-SMADesminKeratinEMAERPRh-CaldesmonCD-10ACTINSTAT-6Agressive Angiomyxoma3+1+1+3+3+3+1+Angiomyfibroblastoma3+1+3+3+3+3+3-/1+Ffibroepithelial stromal polyp3+3+1+1+1+Solitary fibrous tumour3+3+Smooth muscle neoplasm3+3+Spindle cell lipoma3+Angiofibroma of soft tissue1+1+1+2+Superficial myofibroblastoma of the lower female genital tract3+1+3-1+2+3-3-3+3+Cellular Angiofibroma3+2+3-2-2-3-3+3+2-3-(3+): most of cases positive; (2+): half of cases positive; (1+): few/some cases postive; (3-): typically negative; (2-): usually negative

Discussion {#Sec8}
----------

Cellular angiofibroma is a quite recently described rare, benign stromal tumour that occurs equally among men and women: in female patients, CA most frequently arises in the vulvo-vaginal region, although there are described a lot of pelvic and extra-pelvic cases. Women are affected most often in the fifth decade (mean age 46.1 years), earlier than men, affected in the seventh decade. CA is characterized by its small size (mean value 3.6 cm) and usually well-circumscribed margins; it tends to be an asymptomatic and slowly enlarging mass, so CA tends to gradually increase in size after approximately 1--2 asymptomatic years, inducing women to check with their doctor long time after the tumour onset. CA is usually misdiagnosed with a Bartholin's cyst (12/25, 48 % of cases), a not-specific solid mass (7/25, 28 % of cases), vulval cyst (3/25, 12 % of cases), leyomioma (2/12, 8 % of cases) and lipoma (1/25, 4 % of cases). Six extra-pelvic CA are reported in literature. Exceptionally, a young woman presented both vulvar and extra-pelvic CA, particularly two vulvar CA on the right and the left labia majora and three extravulvar CA on the left axilla and both breasts were reported \[[@CR10]\].

Nevertheless exist exceptional early symptomatic forms, as well as our described case-report \[[@CR11]\] in which the woman complained coxalgia due to tumour's position, in retroperitoneal site, very near to obturator nerve.

There are many mesenchymal tumour which enter into the differential diagnosis with CA as spindle cell lipoma, solitary fibrous tumour, mammary-type myofibroblastoma, angiomyfibroblastoma, aggressive angiomyxoma and smooth muscle tumour (Table [4](#Tab4){ref-type="table"}). Exceptionally, CA has been diagnosed with these mesenchymal tumours, such as with lipoma \[[@CR19]\].

*Spindle cell lipoma* was first described by Enzinger and Harvey \[[@CR20]\] in 1975 as a benign lipomatous tumour with a predilection for shoulder, back and posterior neck region of middle-aged to elderly men. Occasional cases may occur in a wide variety of sites, including one reported case arising in the vulva \[[@CR21]\]. The tumour consists of mature adipocytes, bland spindle cells and short bundles of brightly eosinophilic ropy collagen \[[@CR7]\]. In fact, CA and spindle cell lipoma have similar histological features, but can be distinguished by the rarity of spindle cell lipoma in vulvovaginal region and the presence, in CA, of more numerous vessels with thickened, hyalinized walls, compared with capillary-sized thin-walled vessels in spindle cell lipoma. The immunostaining is not helpful because the spindle cells of both tumours are CD34 positive, in particular CD34 is positive in about 60 % of CA and in 100 % of spindle cell lipoma \[[@CR8]\].

*Solitary fibrous tumour* has been reported in a wide variety of locations, including vulva and perineum \[[@CR22], [@CR23]\]. This tumour shows a patternless spindle cell proliferation of alternating hypercellular and hypocellular areas, associated with dense collagen bundles, stromal keloidal-type hyalinization and hemangiopericytoma-like vessels \[[@CR8]\]. Both solitary fibrous tumour and CA may contain fat in the lesion \[[@CR24]\] and show often positivity for CD34 \[[@CR8]\], but CA differs due to more evenly distributed cellularity, bland spindle cells with short bundles of collagen and more rounded small- to medium-sized vessels.

*Mammary-type myofibroblastoma,* as we know for its typical breast localization, has been described also at extramammary locations, especially in the inguinal region, with a male predominance \[[@CR25]\]*.* Grossly, this lesion appears as a well circumscribed, nodular mass and, microscopically, it is composed of spindle cells and adipose tissue, separated by coarse bundles of hyalinized collagen. In comparison of CA, the vessels in mammary-type myofibroblastoma are incospicuous and the spindle cells have a more fascicular arrangement. The tumour cells consistently exhibit coexpression of desmin and CD34 \[[@CR25]\].

All these described tumours share similar morphologic features and are characterized by bland ovoid to spindle-shaped cells with wispy collagen, variably sized thick-walled blood vessels and immunoreactivity to CD34.

In consideration of the clinical features, *aggressive angiomyxoma (AA)* and *angiomyofibroblastoma (AMF)* should also be included in the differential diagnosis of CA. The former is a typical locally recurring tumour of the vulvo-vaginal/perineal/inguinal regions, which occurs mainly in women in third to fifth decades \[[@CR26]--[@CR28]\]. It is easily distinguishable from CA because it is generally a large deep-seated lesion, poorly circumscribed with infiltrative edges: AA tends to display an infiltrative growth with entrapment of mucosal glands, fat, muscle and nerves. Microscopically, aggressive angiomyxoma is hypocellular, compared with CA, and it is composed of short spindle tumour cells with minimal atypia in myxoid stroma. Small clusters of smooth muscle cells surrounding or "spinning off from" blood vessels are a characteristic feature of AA \[[@CR3]\]. There is a variable positivity for desmin, smooth muscle actin and CD34 \[[@CR7], [@CR27], [@CR28]\].

*Angiomyofibroblastoma* is a benign tumour most commonly occurring in the vulva of peri- and post-menopausal women \[[@CR29], [@CR30]\]. Like CA, AMF is well circumscribed, even well demarcated, usually with a thin fibrous capsule but, unlike to CA, it is characterized by alternating hypocellular and hypercellular areas, together with multinucleate cells and epithelioid or plasmacytoid cells arranged in cords and nets around vessels. In fact, the characteristic feature of angiomyofibroblastoma is the perivascular accentuation of tumor cells \[[@CR29], [@CR30]\]. In aid to differential diagnosis, the immunochemistry is very useful because the tumour cells of AMF express desmin and rarely CD34 and smooth muscle actin \[[@CR7], [@CR29], [@CR30]\].

Finally, vulvar *smooth muscle tumours* can be easily distinguished from CA because the latter lacks typical features of smooth muscle differentiation and it is usually desmin negative. The smooth muscle neoplasm are classically composed of cells with blunt-ended nuclei and eosinophilic cytoplasm, although these histological features could be absent when the tumour is localized in the vulvovaginal region.

The immunohistochemical features of CA may be helpful in differential diagnosis with the other vulvovaginal soft tissue tumours. An interesting immunohistochemical finding is the Estrogen and/or Progesterone receptors (ER/PR) expression by the CA. The occurrence of CA during menopausal transition and post-menopausal period and the description of a two cases associated with long-term estrogen replacement therapy \[[@CR11], [@CR15]\] support the hypothesis of an hormonal pathogenetic origin. However, the direct role of these steroids in the CA pathogenesis still remains unclear, since a subset of mesenchymal cells of the distal female genital tract normally expresses these receptors and, at the same time, the neoplastic cells in other soft tissue disorders, arising from the vulva, may also show immunoreactivity for ER and/or PR \[[@CR31]\].

Immunohistochemistry may be also helpful in differential diagnosis between *usual* CA and CA with *atypia or sarcomatous transformation*. p16 expression is commonly negative in *usual* CA whilst is multifocal or diffuse in CA with *atypia or sarcomatous transformation* \[[@CR9]\]. The p16 and p53 represent tumour suppressor genes involving in the regulation of molecular pathways that may play a role in the tumour progression in sarcomas: overexpression of p16 may participate in the molecular mechanisms underlying the atypical or sarcomatous transformation seen in some subset of CA \[[@CR9]\].

Recently fluorescent *in situ* hybridization (FISH) \[[@CR13]\] has shown a genetic relationship between CA, mammary-type myofibroblastoma and spindle cell lipoma. The same monoallelic or biallelic loss of retinoblastoma (RB) 1 (13q14), suggested a spectrum of one entity with morphological variations dependent on anatomic location. This argument doesn't apply to solitary fibrous tumour as pubblished by Fritchie et al. \[[@CR26]\] that shows the absence of monoallelic/biallelic RB1 loss by FISH, arguing against the concept the solitary fibrous tumour is genetically related to the other three entities.

RB is an important tumor suppressor protein that plays a crucial role in cell cycle progression \[[@CR32]\]. RB gene is located at 13q14. Disruptions to the RB protein and to the pathway controlled by RB confer proliferative advantage to tumor cells \[[@CR33]\]. In 13q14 gene is located also a tumor suppressor called Forkhead box protein O1 (FOXO1) \[[@CR34]\]. FOXO1 is a transcription factor associated with apoptosis, cell cycle regulation, DNA repair and resistance to oxidative stress \[[@CR34]\]. A loss of FOXO1 expression was recently associated with CA \[[@CR35]\]. FOXO1 transcription factor induces an increased expression of manganese superoxide dismutase (MnSOD) resulting in an elimination of the reactive oxygen species (ROS) \[[@CR36]\]. Hence, loss of FOXO1 expression is associated with a decreased expression of MnSOD and, as consequence, an increased intracellular ROS generation causing mutations in proto-oncogenes and tumor suppressor genes \[[@CR37]\]. In fact, increased intracellular ROS induces p38 mitogen-activated protein (MAPK) pathway and may be linked to the tumorigenesis \[[@CR36]--[@CR38]\].

ROS can cause tumor development through cellular proliferation, tumor cell invasion, angiogenesis and cancer stem cell survival \[[@CR37]\]. Also mammary and vaginal myofibroblastomas can present a monoallelic deletion of FOXO1 \[[@CR31]\]. Hence, RB1 and FOXO1 loss of expression could be implicated in the pathogenesis of CA \[[@CR13], [@CR39]\]. RB1 and FOXO1 FISH analysis could be used to support CA diagnosis but the specificity is uncertain \[[@CR13]\].

Also CA pathogenesis is still unclear, both sexual hormones and ROS has been proposed. Although human papillomavirus (HPV) E7 oncoprotein bind RB protein causing a loss of function \[[@CR40]\], to our knowledge no role of infections in the pathogenesis of CA has been studied.

CA appears to behave in a benign fashion, since there is no report of tumours that progressed with metastasis and there is described only a recurrent case \[[@CR12]\]. The primary and the recurrent CA consisted of a well circumscribed solid white mass of 4 and 6.5 cm respectively. The histology of both lesions didn't consistently differ: the recurrent lesion showed foci of increased cellularity and decreased vascularity compared with the original specimen although there were no histological features to suggest malignancy and 33 months after the excision of the recurrent CA, there were no evidences of further local recurrence.

In the majority of the analysed cases, the surgical approach consists of a simple local excision or a "shelling out" and these treatments seem to be adequate also in case of atypia and/or sarcomatous transformation where the literature suggests a radical excision with free margins \[[@CR9], [@CR12]\]. To date, we are not aware of any cases of metastases of these tumours with atypia/sarcomatous features, suggesting that morphological atypical or sarcomatous aspects don't necessarily confer an aggressive biologic behaviour to CA. Moreover, only 5 cases (5/18, 27.8 %) of re-excision because involved surgical margins has been reported but this method doesn't represent an elective procedure because the tumour is usually treated with a local excision also when there are positive surgical margins, as showed in the remaining 13 cases (13/18, 72.2 %) with positive surgical margins, although no recurrences or metastasis have been reported. Therefore, considering that also cases of CA with positive margins don't recur, no wide excision should be required. Given the relative sensitivity of the most frequently affected anatomic sites, there seems to be no justification for attempting to obtain a larger surgical margins \[[@CR3]\].

Conclusions {#Sec9}
===========

In summary, CA in women represents a distinct benign neoplasm with a broad anatomic distribution even if it is mainly localized in the vulvo-vaginal area. This lesion may exhibit some variations in its phenotypic features, as well as atypia and morphologic features of sarcomatous transformation but these characteristics seem not to predispose to a malignant fashion and recurrences. For these reasons, a treatment of simple local excision or a "shelling out" of the lesion appear to be adequate and effective to avoid recurrences and injuries to surrounding tissues.

CA

:   Cellular angiofibroma

AA

:   Aggressive angiomyxoma

AMF

:   Angiomyofibroblastoma

ER

:   Estrogen receptor

PR

:   Progesterone receptor

FISH

:   Fluorescent *in situ* hybridization

RB

:   Retinoblastoma

FOXO1

:   Forkhead box protein O1

MnSOD

:   Manganese superoxide dismutase

ROS

:   Reactive oxygen species

MAPK

:   Mitogen-activated protein

HPV

:   Human papillomavirus

**Competing interests**

The authors declare that they have no competing interests.

**Author's contributions**

VDM and SS substantially contributed to design the study, to collect data and to analyze the results. AC partecipated in revising pathological and immunohistochemical data and provided for the images. LA helped to conceived of the manuscript. MA and GBLS revised critically the work and they gave final approval of the version to be published. All authors read and approved the final manuscript.

The authors thank the pathologists and clinicians who kindly contributed to clinical and follow-up data: Dr Nebojosa N. Arsenovic, UK; Dr Jean Louis Dargent, Belgium; Dr Adilha Rua Micheletti, Brasil; Dr Jose Fernando Val Bernal, Spain.
